Open AccessNutraceuticals in the management of patients with statin‐associated muscle symptoms, with a note on real‐world experience
Author(s) -
Ward Natalie C.,
Pang Jing,
Ryan Jacqueline D.M.,
Watts Gerald F.
Publication year - 2018
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22862
Subject(s) - medicine , nutraceutical , statin , atherosclerotic cardiovascular disease , disease , hydroxymethylglutaryl coa reductase inhibitors , intensive care medicine , ldl cholesterol , physical therapy , cholesterol , pathology
There is considerable evidence for the role of low‐density lipoprotein cholesterol (LDL‐C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL‐C and lower risk of cardiovascular disease, a considerable number of patients develop muscle‐related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL‐C–lowering therapy in statin‐intolerant patients, with evidence from our own clinical practices.